Motolimod

Research use only, not for human use.

Motolimod (VTX-2337) is an effective and specific Toll-like receptor (TLR) 8 agonist (EC50: 100 nM), > 50-fold selectivity over TLR7.

Motolimod, also known as VTX-2337, is a small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities. TLR8 agonist VTX-2337 binds to TLR8, present in cutaneous dendritic cells, monocytes/macrophages, and mast cells, which may result in the activation of the central transcription factor nuclear factor-B, the secretion of proinflammatory cytokines and other mediators, and a Th1-weighted antitumoral cellular immune response. Primarily localized to endosomal membranes intracellularly, TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in the innate immune system.

——

——

VTX-2337 | VTX 2337 | VTX2337 | Motolimod

Neuroscience

GluR

TLR8

Cancer

——

926927-61-9

458.6

C28H34N4O2

>98% (HPLC)

DMSO : 50 mg/mL. 109.03 mM;

CCCN(CCC)C(=O)C1=Cc2c(cc(cc2)c2ccc(cc2)C(=O)N2CCCC2)N=C(N)C1

2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide

(-20℃)

With Ice Pack

≥ 2 years